AU2024283291A1 - Anti-synaptotagmin 2 antibody - Google Patents
Anti-synaptotagmin 2 antibodyInfo
- Publication number
- AU2024283291A1 AU2024283291A1 AU2024283291A AU2024283291A AU2024283291A1 AU 2024283291 A1 AU2024283291 A1 AU 2024283291A1 AU 2024283291 A AU2024283291 A AU 2024283291A AU 2024283291 A AU2024283291 A AU 2024283291A AU 2024283291 A1 AU2024283291 A1 AU 2024283291A1
- Authority
- AU
- Australia
- Prior art keywords
- antibody
- present
- motor neuron
- amino acid
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Genetics & Genomics (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Wood Science & Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Neurology (AREA)
- Mycology (AREA)
- Neurosurgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023090263 | 2023-05-31 | ||
| JP2023-090263 | 2023-05-31 | ||
| PCT/JP2024/019803 WO2024248063A1 (ja) | 2023-05-31 | 2024-05-30 | 抗シナプトタグミン2抗体 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2024283291A1 true AU2024283291A1 (en) | 2026-01-08 |
Family
ID=93658011
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2024283291A Pending AU2024283291A1 (en) | 2023-05-31 | 2024-05-30 | Anti-synaptotagmin 2 antibody |
Country Status (4)
| Country | Link |
|---|---|
| EP (1) | EP4722242A1 (https=) |
| JP (1) | JPWO2024248063A1 (https=) |
| AU (1) | AU2024283291A1 (https=) |
| WO (1) | WO2024248063A1 (https=) |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MXPA04005010A (es) | 2001-11-26 | 2005-04-08 | Advanced Cell Tech Inc | METODO PARA HACER Y USAR NUCLEOS CELULARES SOMáTICOS METODOS PARA HACER Y USAR NUCLEOS CELULARES SOMáTICOS HUMANOS REPROGRAMADOS Y CELULAS DEL TALLO HUMANAS AUTOLOGAS E ISOGENICAS. |
| JP2008143867A (ja) | 2006-12-12 | 2008-06-26 | Institute Of Physical & Chemical Research | シナプス形成促進剤 |
| JP2012092048A (ja) | 2010-10-27 | 2012-05-17 | Keio Gijuku | 軽度認知障害の治療用医薬剤、初期認知症の治療用医薬剤、神経細胞の樹状突起形成促進剤、神経細胞のシナプス形成促進剤、検定方法およびスクリーニング方法 |
| CN103627676A (zh) * | 2013-05-10 | 2014-03-12 | 深圳大学 | 多头绒泡菌14-3-3蛋白单克隆抗体及其制备方法 |
| JP7323874B2 (ja) | 2019-03-27 | 2023-08-09 | 国立大学法人東北大学 | 神経軸索分岐異常の改善剤 |
| JP7849713B2 (ja) | 2019-07-05 | 2026-04-22 | 株式会社Jiksak Bioengineering | 神経細胞のシナプス形成誘導方法および該方法に用いるマイクロビーズ |
| JP2022053535A (ja) | 2020-09-24 | 2022-04-05 | 株式会社Jiksak Bioengineering | シナプス形成を促進するための組成物 |
| US20220251241A1 (en) * | 2021-02-08 | 2022-08-11 | Ngm Biopharmaceuticals, Inc. | Htra1-binding agents and methods of use thereof |
| JP2023028848A (ja) | 2021-08-20 | 2023-03-03 | 株式会社Jiksak Bioengineering | シナプス形成促進剤 |
| JP7851719B2 (ja) | 2021-12-17 | 2026-04-27 | シャープ株式会社 | 表示装置、および、テレビジョン受像機 |
| WO2023210585A1 (ja) | 2022-04-25 | 2023-11-02 | 株式会社Jiksak Bioengineering | 標的化剤 |
-
2024
- 2024-05-30 JP JP2025524148A patent/JPWO2024248063A1/ja active Pending
- 2024-05-30 WO PCT/JP2024/019803 patent/WO2024248063A1/ja not_active Ceased
- 2024-05-30 AU AU2024283291A patent/AU2024283291A1/en active Pending
- 2024-05-30 EP EP24815544.2A patent/EP4722242A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2024248063A1 (ja) | 2024-12-05 |
| JPWO2024248063A1 (https=) | 2024-12-05 |
| EP4722242A1 (en) | 2026-04-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20250277028A1 (en) | Targeting agent | |
| CN104781278B (zh) | 针对tau的抗体 | |
| CN116966293A (zh) | 脑信号蛋白-4d结合分子治疗神经变性疾病的用途 | |
| Jiang et al. | Single-domain antibody-based protein degrader for synucleinopathies | |
| González et al. | Frizzled 1 and Wnt1 as new potential therapeutic targets in the traumatically injured spinal cord | |
| AU2024283291A1 (en) | Anti-synaptotagmin 2 antibody | |
| AU2024281601A1 (en) | Anti-synaptotagmin 2 antibody | |
| WO2025084394A1 (ja) | 抗シナプトタグミン2抗体 | |
| WO2025084396A1 (ja) | 抗シナプトタグミン2抗体 | |
| WO2025084393A1 (ja) | 抗シナプトタグミン2抗体 | |
| WO2025084397A1 (ja) | 抗シナプトタグミン2抗体 | |
| WO2025084395A1 (ja) | 抗シナプトタグミン2抗体 | |
| WO2025089342A1 (ja) | 抗シナプス小胞糖タンパク質2c抗体 | |
| WO2025089341A1 (ja) | 抗シナプス小胞糖タンパク質2c抗体 | |
| WO2025089344A1 (ja) | 抗シナプス小胞糖タンパク質2c抗体 | |
| WO2025089343A1 (ja) | 抗シナプス小胞糖タンパク質2c抗体 | |
| WO2025089345A1 (ja) | 抗シナプトジャイリン3抗体 | |
| WO2025089346A1 (ja) | 抗シナプトフィジン抗体 | |
| WO2025089349A1 (ja) | 抗シナプトフィジン抗体 | |
| WO2025089347A1 (ja) | 抗シナプトフィジン抗体 | |
| WO2025089348A1 (ja) | 抗シナプトフィジン抗体 | |
| WO2023220639A2 (en) | Methods and compositions for improved memory in the aging | |
| CA3257052A1 (en) | Targeting agent | |
| US20250346635A1 (en) | Vascular endothelial growth factor receptor-1 (vegfr-1) inhibitors for promoting myelination and neuroprotection | |
| Huang et al. | Isolation, culture, and characterization of primary endothelial cells and pericytes from mouse sciatic nerve |